Virpax Pharmaceuticals Q1 EPS $(0.44) Up From $(0.60) YoY
Virpax Pharmaceuticals (NASDAQ:VRPX) reported quarterly losses of $(0.44) per share. This is a 26.67 percent increase over losses of $(0.60) per share from the same period last year.
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.
55 Stocks Moving In Friday’s Mid-Day Session
Gainers
Swvl Holdings Corp. (NASDAQ: SWVL) surged 24.4% to $7.50. Swvl Holdings 13D Filing from investor Ahmed Sabbah showed a new 6.4% stake in the company.
24 Stocks Moving in Friday’s Pre-Market Session
Gainers
Vinco Ventures, Inc. (NASDAQ: BBIG) shares rose 35% to $3.47 in pre-market trading. Vinco Ventures set record date as May 18, 2022 For dividend of shares related to Cryptyde deal. The dividend is expected to be distributed on May 27, 2022.
Virpax Pharmaceuticals Enters Cooperative Research And Development Agreement With US Army Institute of Surgical Research To Evaluate Probudur
Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder,
Virpax Completes All FDA-Required Pre-Clinical Studies For Epoladerm
Preparing Investigational New Drug Application for Submission Upon Completion of Canadian Clinical Study
Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a
Virpax Pharma Expands AnQlar Worldwide Licensing Pact In COVID-19
Virpax Pharmaceuticals Inc (NASDAQ: VRPX)
